Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 by Intellectual Property Watch 1 Comment This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is.
Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 by Intellectual Property Watch 2 Comments Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado.
Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 by Intellectual Property Watch 7 Comments The Brazilian government’s plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker.
How To Discover Valuable Patents 27/04/2018 by Intellectual Property Watch Leave a Comment Bastian July writes: In May 1968, the submarine USS Scorpion disappeared after a tour of duty in the North Atlantic. The initial search area was a circle twenty miles wide and thousands of feet deep. Instead of asking one or two experts for input, Navy officer John Craven assembled a large group of independent experts with a wide range of knowledge. The group included mathematicians, submarine specialists, salvage men and many others. Combining their knowledge, Craven was able to estimate the submarine’s likely location. It was found 200 yards from the group’s collective estimate. But can you also turn to the Wisdom of the Crowd when it comes to discovering the fortunes lying hidden in patents?
Adopting An Open Innovation Perspective For Patent Policy For The Internet Of Things 26/04/2018 by Intellectual Property Watch 1 Comment The Internet of Things is a prototypical technology space, where small and medium sized enterprises (SMEs), universities and their spin-outs as well as big corporations alike could constitute a fruitful innovation ecosystem. All these players could thrive in the spirit of Open Innovation, so to collectively re-invent the future of the internet and patents could take the role of promoting tech transfer, knowledge exchange and spur secondary markets for intellectual property.
Interview With Dominik Thor, Founder Of IPCHAIN Database 20/04/2018 by Intellectual Property Watch 2 Comments Distributed ledger technology, commonly called a Blockchain, has recently become a highly popular term in many different industries for its cost-saving and operational risk reducing potential. In this interview with Intellectual Property Watch, Dominik Thor, the founder of IPCHAIN Database, a startup that focuses on IP protection through the use of Blockchain, explains about the ways this new technology can revolutionise the IP sector.
Ending Unauthorised Access To Genetic Resources (aka Biopiracy): Bounded Openness 06/04/2018 by Intellectual Property Watch 7 Comments “Access to genetic resources” and “the fair and equitable sharing of benefits arising from their utilization” have beleaguered all thirteen Conferences of the Parties to the 1993 United Nations Convention on Biological Diversity (CBD), a group of academics writes. The expression in quotes constitutes the third objective of the Convention and is intertwined with the first two, conservation and sustainable use. It goes by the acronym “ABS”. Despite 25 years of efforts and an annual bio-economy of nearly one trillion dollars, few contracts have ever been concluded. And of those very few, the monetary benefits are so low that contracting parties are loathe to disclose them. The “Brazilian ABS Law” of 2015, which came into effect on 6 November 2017, even allows royalties on net sales to be as low as one tenth of one percent. In the words of one distinguished legal scholar, Users are paying “peanuts for biodiversity.”
Introduction Of A Grace Period In Europe 13/03/2018 by Intellectual Property Watch Leave a Comment The protection of inventions is a cornerstone to encourage innovation as engine of economic growth. As one of the world‘s leading centres for innovation, the level of scientific and technological performance in Germany is very high, thanks to an excellent research landscape and a good technological and economic basis. But the global innovation competition is intensifying, and new competitors are seeking to enter international markets. However, Germany is falling short of its potential when it comes to leveraging technology to create new products, writes Michael Kahnert.
New IP-Sharing Framework To Accelerate R&D 12/03/2018 by Intellectual Property Watch Leave a Comment Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef.
What We Know – And What We Don’t – About Counterfeit Goods And Small Parcels 08/03/2018 by Intellectual Property Watch 1 Comment Kasie Brill writes: Cross-border e-commerce is growing exponentially. Consumers can purchase products from all over the world and have them delivered straight to their doors with just the click of a button. In fact, the U.S. Postal Service’s (USPS) international small parcel business increased 232% from 2013 to 2017, when it received nearly half a billion packages. Out of those half a billion packages, USPS only had critical safety information on 36% of them. In other words, millions of packages reached American consumers with little or no security screening at all. Though most of these packages contained exactly what the customer ordered, counterfeiters have discovered that small parcels are an easy means to distribute fake and often dangerous goods.